Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML : Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto ( GIMEMA) and German MDS Study Group
British Journal of Haematology · 03.11.2026
DOI: 10.1111/bjh.70874 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 03.11.2026. Verfasst von Julia Stomper und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Astellas Pharma, Bristol-Myers Squibb.
Abstract (Originalsprache)
Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies. We investigated the association between HbF and treatment outcome in the randomized phase 3 European Organisation for Research and Treatment of Cancer (EORTC)‐1301 trial AML21, which included 606 fit, older AML patients who received 10‐day decitabine or ‘3 + 7’ chemotherapy as induction. HbF was measured twice in the decitabine arm ( n = 135) and at baseline in the 3 + 7 arm ( n = 97). In the decitabine arm, HbF increase from baseline to day 10 was associated with increased odds of reaching complete remission (CR) or CR with incomplete count recovery (CRi) (odds ratio [OR] 2.40, 95% confidence interval [CI] 1.15–5.02, p = 0.020). The hazard ratio (HR) for death comparing patients with HbF increase to those without was 0.83 (95% CI 0.55–1.28, p = 0.40). Baseline HbF in the decitabine arm was not associated with CR/CRi (OR 0.89, 95% CI 0.45–1.75, p = 0.73) or overall survival (HR 0.86, 95% CI 0.58–1.28, p = 0.47). In conclusion, this large prospective study adds to the body of evidence that HbF is an easy‐to‐measure early biomarker for response to HMA treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany.
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Medical Center, Aachen, Germany.
- EORTC Headquarters, Brussels, Belgium.
- Collaborative Research Institute Intelligent Oncology (CRIION), Freiburg, Germany.
- Department of Hematology, Caen University Hospital, Caen, France.
- Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
ORCID-Profile: Julia Stomper, Michal Kicinski, Thomas Meyer, Sylvain Chantepie, Ernesta Audisio, Andreas Neubauer, Robin Foà, Walter J F M Van der Velden, Anna Candoni, Radovan Vrhovac, Gianluca Gaidano, Catharina Van Elssen, Christian Junghanß, Stephanie Antunes, Frédéric Baron, Adriano Venditti, Michael Lübbert
Förderung
- Deutsche Forschungsgemeinschaft
- Astellas Pharma
- Bristol-Myers Squibb
- Immunocore
- Johnson and Johnson
- MSD
- Pierre Fabre
- Janssen Pharmaceuticals
Zitieren
APA
Stomper, J., Kicinski, M., Ma, T., Meyer, T., Chantepie, S., Noppeney, R., Luppi, M., Audisio, E., Griškevičius, L., Neubauer, A., Foà, R., Van der Velden, W. J. F. M., Candoni, A., Vrhovac, R., Gaidano, G., Van Elssen, C., Hoogendoorn, M., Musso, M., Olivieri, A., …, & Lübbert, M. (2026). Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML : Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto ( GIMEMA) and German MDS Study Group. British Journal of Haematology. https://doi.org/10.1111/bjh.70874
Vancouver
Stomper J, Kicinski M, Ma T, Meyer T, Chantepie S, Noppeney R, et al. Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML : Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto ( GIMEMA) and German MDS Study Group. British Journal of Haematology. 2026. doi:10.1111/bjh.70874
BibTeX
@article{Stomper2026,
author = {Stomper, Julia and Kicinski, Michal and Ma, Tobias and Meyer, Thomas and Chantepie, Sylvain and Noppeney, Richard and Luppi, Mario and Audisio, Ernesta and Griškevičius, Laimonas and Neubauer, Andreas and Foà, Robin and Van der Velden, Walter J F M and Candoni, Anna and Vrhovac, Radovan and Gaidano, Gianluca and Van Elssen, Catharina and Hoogendoorn, Mels and Musso, Maurizio and Olivieri, Attilio and Junghanß, Christian and Bissé, Emmanuel and Antunes, Stephanie and Baron, Frédéric and Venditti, Adriano and Jansen, Joop H and Wijermans, Pierre W and Huls, Gerwin and Lübbert, Michael},
title = {Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML : Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto ( GIMEMA) and German MDS Study Group},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70874}
}
EUVIMED